Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Transcriptome-Wide Association Study Identifies New Candidate Susceptibility Genes for Glioma

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. A large-cohort, longitudinal study determines pre-cancer disease routes across different cancer types

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Genetic data from nearly 63,000 women of European descent predicts DNA methylation biomarkers and epithelial ovarian cancer risk

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Nutrition screening and assessment tools for patients with cancer and survivors of cancer: a systematic review protocol

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Felodipine and renal function in lung transplantation: A randomized placebo-controlled trial

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Anticancer drugs targeted to the nuclear enzyme DNA topoisomerase II are classified as poisons that lead to DNA breaks or catalytic inhibitors that appear to completely block enzyme activity. To examine the effects of the bisdioxopiperazine class of catalytic inhibitors to topoisomerase II, we investigated a Chinese hamster ovary (CHO) subline selected for resistance to ICRF-159 (CHO/159-1). Topoisomerase IIalpha content in CHO/159-1 cells was reduced by 40-50%, compared to wild-type CHO cells, whereas the beta isoform was increased by 10-20% in CHO/159-1 cells. However, the catalytic activity of topoisomerase II in nuclear extracts from CHO/159-1 cells was unchanged, as was its inhibition by the topoisomerase II poison etoposide (VP-16). No inhibition of topoisomerase II catalytic activity by ICRF-187 was seen in CHO/159-1 cells up to 500 microM, whereas inhibition was evident at 50 microM in wild-type CHO cells. VP-16-mediated DNA single-strand breaks and cytotoxicity were similar in the two sublines. ICRF-187 could abrogate these VP-16 effects in the wild-type line but had no effect in CHO/159-1 cells. Western blots of topoisomerase IIalpha after incubation of CHO cells with ICRF-187 demonstrated a marked band depletion, whereas this effect was completely lacking in CHO/159-1 cells, and an equal effect of VP-16 was observed in both lines. These data imply that the CHO/159-1 topoisomerase IIalpha lacks sensitivity to bisdioxopiperazines and that the mechanism of resistance in this cell line does not confer cross-resistance to topoisomerase II poisons, suggesting that mutations conferring resistance to bisdioxopiperazines can occur at sites distinct from those responsible for resistance to complex stabilizing agents. Accordingly, CHO/159-1 cDNA showed two heterozygous mutations in the proximal NH2-terminal part of topoisomerase IIalpha (Tyr49Phe and delta 309Gln-Gln-Ile-Ser-Phe313), which is in contrast to those induced by topoisomerase II poisons, which cluster further downstream. Site-directed mutagenesis and transformation of the homologous Tyr50Phe coding mutation in human topoisomerase IIalpha in a temperature-conditional yeast system demonstrated a high-level resistance to ICRF-193, compared to cells expressing wild-type cDNA, but none toward the poisons VP-16 or amsacrine, thus confirming that the Tyr50Phe mutation confers specific resistance to bisdioxopiperazines. Thus, these results indicate that the region of the protein involved in ATP-binding also plays a critical role in sensitivity to bisdioxopiperazines, a result consistent with the known requirement for the formation of an ATP-bound closed clamp for bisdioxopiperazine activity. These results may enable a more precise understanding of the interaction of topoisomerase II-directed drugs with their target enzyme.

Original languageEnglish
JournalCancer Research
Volume58
Issue number7
Pages (from-to)1460-8
Number of pages9
ISSN0008-5472
Publication statusPublished - 1 Apr 1998

    Research areas

  • Amino Acid Sequence, Animals, Antigens, Neoplasm, Antineoplastic Agents/pharmacology, Antineoplastic Agents, Phytogenic/pharmacology, Base Sequence, Blotting, Western, CHO Cells/drug effects, Cricetinae, DNA Topoisomerases, Type II/metabolism, DNA, Neoplasm/analysis, DNA-Binding Proteins, Drug Resistance, Neoplasm, Enzyme Inhibitors/pharmacology, Etoposide/pharmacology, Isoenzymes/antagonists & inhibitors, Molecular Sequence Data, Mutation, Piperazines/pharmacology, Razoxane/pharmacology, Saccharomyces cerevisiae/enzymology, Topoisomerase II Inhibitors

ID: 59178564